Cargando…

Lewy Body Dementia Association’s Industry Advisory Council: proceedings of the second annual meeting

In 2019, the Lewy Body Dementia Association formed an Industry Advisory Council to bring together a collaborative group of stakeholders with the goal of accelerating clinical research into Lewy body dementia treatments. At the second annual meeting of the Industry Advisory Council, held virtually on...

Descripción completa

Detalles Bibliográficos
Autores principales: Goldman, Jennifer G., Boeve, Bradley F., Armstrong, Melissa J., Galasko, Doug R., Galvin, James E., Irwin, David J., Leverenz, James B., Marder, Karen, Abler, Victor, Biglan, Kevin, Irizarry, Michael C., Keller, Bill, Lai, Robert, Munsie, Leanne, Belleville, Michael, Chaney, Ondrea, Richard, Ian, Taylor, Angela, Graham, Todd
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8265285/
https://www.ncbi.nlm.nih.gov/pubmed/34238345
http://dx.doi.org/10.1186/s13195-021-00868-7
Descripción
Sumario:In 2019, the Lewy Body Dementia Association formed an Industry Advisory Council to bring together a collaborative group of stakeholders with the goal of accelerating clinical research into Lewy body dementia treatments. At the second annual meeting of the Industry Advisory Council, held virtually on June 18, 2020, the key members presented ongoing and planned efforts toward the council’s goals. The meeting also featured a discussion about the effects of the COVID-19 pandemic on Lewy body dementia clinical research, lessons learned from that experience, and how those lessons can be applied to the design and conduct of future clinical trials. This report provides a brief summary of the meeting proceedings with a focus on efforts to improve and adapt future Lewy body dementia clinical research.